• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ypsomed partners with CamDiab on smartphone-based automated insulin delivery

March 22, 2022 By Sean Whooley

Ypsomed CamDiab YpsoPump Dexcom G6
[Image from Ypsomed]
Ypsomed (SWX:YPSN) announced today that it partnered with CamDiab to collaborate on managing automated insulin delivery with a mobile app.

The partnership aims to launch CamDiab’s CamAPS FX app for managing glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach, for automated insulin delivery (AID) with Ypsomed’s MyLife YpsoPump system during the first half of 2022.

Burgdorf, Switzerland-based Ypsomed said in a news release that the launch will start in select major countries in Europe, with other territories to follow over the course of 2022. Patients will be able to connect the MyLife YpsoPump to the MyLife CamAPS FX Android mobile app, enabling algorithm-based insulin delivery support, including bolus, from the personal smartphone.

The MyLife CamAPS FX Android app has compatibility with the Dexcom G6 CGM and represents the first CE-marked algorithm on a mobile app, Ypsomed said. The app automatically adjusts insulin delivery on the pump based on the G6’s glucose readings.

If a user overestimates or underestimates carbohydrates, the algorithm adjusts insulin delivery to prevent glucose levels from reaching levels that are too high or too low.

“We are very excited to work together with CamDiab, a trailblazer in developing interoperable loop systems,” Ypsomed CEO Simon Michel said in the release. “Together, we can make a step further in achieving our common goal, making life of people living with diabetes as easy as possible. We are looking forward to rolling out this solution in Europe over the coming months, first on Android and then also on iOS.”

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: CamDiab, Dexcom, Ypsomed

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS